Search Clinical Trials
Sponsor Condition of Interest |
---|
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
Bristol-Myers Squibb
Sjögren's Syndrome
The purpose of this study is to assess the safety and efficacy of two doses of
Deucravacitinib in adult participants with Active Sjögren's Syndrome. expand
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome. Type: Interventional Start Date: Sep 2023 |
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive...
NRG Oncology
HER2-positive Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with
early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and
receive HER2-directed therapy, and are randomized to not receive adjuvant breast
radiotherapy versus those who are randomized to... expand
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care. Type: Interventional Start Date: Mar 2023 |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score...
NRG Oncology
Stage I Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy
results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor
recurrence (IBTR) compared to breast conservation with breast radiation and endocrine
therapy. expand
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy. Type: Interventional Start Date: Jun 2021 |
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Institut de Recherches Internationales Servier
Acute Lymphoblastic Leukemia
The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate
the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients
with Philadelphia-negative Acute Lymphoblastic Leukemia. expand
The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia. Type: Interventional Start Date: Jul 2021 |
Dry Needling in Multiple Sclerosis
University of Kansas Medical Center
Multiple Sclerosis
Spasticity
The investigators are doing this study to see if a treatment called dry needling improves
muscle spasticity (muscle tightness) in people who have Multiple Sclerosis. Dry needling
involves using tiny needles, like those in acupuncture, to target some muscles, like calf
muscles. It differs from traditional... expand
The investigators are doing this study to see if a treatment called dry needling improves muscle spasticity (muscle tightness) in people who have Multiple Sclerosis. Dry needling involves using tiny needles, like those in acupuncture, to target some muscles, like calf muscles. It differs from traditional acupuncture as it focuses on treating or managing muscle spots, aiming to reduce muscle stiffness and pain. Dry needling may offer a minimally-invasive and medication-free approach to improve muscle spasticity. The investigators hope to see if dry needling also helps enhance balance and walking abilities. This might provide potential improvements inoverall mobility and balance. Type: Interventional Start Date: May 2024 |
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI...
Cardiff Oncology
Metastatic Colorectal Cancer
CRC
KRAS/NRAS Mutation
The purpose of this study is to assess 2 different doses of onvansertib to select the
lowest dose that is maximally effective, and to assess the safety, efficacy,
pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI +
bevacizumab or FOLFOX + bevacizumab in patients with... expand
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting. Type: Interventional Start Date: Feb 2024 |
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
Contineum Therapeutics
Relapsing Remitting Multiple Sclerosis
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with
relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate
cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total
duration of approximately 30 weeks. expand
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks. Type: Interventional Start Date: Nov 2023 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic...
Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
BMS-986278 in participants with Idiopathic Pulmonary Fibrosis. expand
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis. Type: Interventional Start Date: Sep 2023 |
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
argenx
Multifocal Motor Neuropathy
This prospective longitudinal study will follow participants with Multifocal Motor
Neuropathy over time and collect data on their clinical outcomes, quality of life, and
use of health care resources. Participants will follow their regular visit schedule with
their treating physician, except for an... expand
This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered. Type: Observational Start Date: Nov 2023 |
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
Tenax Therapeutics, Inc.
Pulmonary Hypertension
This study will evaluate the efficacy of TNX-103 (levosimendan) compared with placebo in
subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1
to Week 12). expand
This study will evaluate the efficacy of TNX-103 (levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12). Type: Interventional Start Date: Jan 2024 |
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Schrödinger, Inc.
Acute Myeloid Leukemia
High-Risk and Very High-Risk Myelodysplastic Syndromes
The purpose of this study is to evaluate safety and tolerability and to determine the
maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921. expand
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-2921. Type: Interventional Start Date: Sep 2023 |
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab)...
Pfizer
Diffuse Large B-Cell Lymphoma
The purpose of this study is to learn about the effects of two study medicines
(maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of
diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means
has returned after last treatment. Refractory... expand
The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means has returned after last treatment. Refractory means that it has not responded to last treatment. The two study medicines are given after a single dose of obinutuzumab which is the third study medicine. DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. This study is seeking adult participants who: - Have histologically confirmed diagnosis of DLBCL - Have received at least two first lines of treatment for NHL. - Are unable or unwilling to undergo a stem cell transplant or CAR-T cell therapy. Stem cell transplant is a procedure in which a patient receives healthy blood-forming cells to replace their own stem cells that have been destroyed by treatment. A CAR-T therapy is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. Everyone in this study will receive all three medicines at the study site by intravenous (IV) infusion which is given directly into a vein. The two study medicines (maplirpacept [PF-07901801] and glofitamab) will be given in 21-day cycles. At Cycle 0, participants will receive a single dose of obinutuzumab pre-treatment followed by two step-up doses of glofitamab. The combination of maplirpacept (PF-07901801) with glofitamab full dose will be administered for the first time at Cycle 1 Day 1. Maplirpacept (PF-07901801) will be given weekly for the first three cycles and then every three weeks. Glofitamab will be given every 3 weeks for approximately 9 months. Thereafter participants will continue to receive maplirpacept alone. Maplirpacept (PF-07901801) will be given at different doses to different participants. Everyone taking part will receive the same fixed doses of glofitamab and obinutuzumab studied in patients with DLBCL. The study will compare the experiences of people receiving different doses of maplirpacept (PF-07901801). This will help to determine what dose is safe and effective when given with the other 2 study medicines. Type: Interventional Start Date: Aug 2023 |
SUBLOCADE Long-term Outcomes
Indivior Inc.
Opioid Use Disorder
This study will provide the opportunity to generate data on the long-term use of
SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle,
health, and sociodemographic factors that are part of the recovery process. Long-term
patterns of abstinence/opioid misuse as well as... expand
This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, this study will observe participants up to a maximum of 4 years. Type: Observational Start Date: Aug 2023 |
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants...
Iovance Biotherapeutics, Inc.
Metastatic Melanoma
Unresectable Melanoma
Melanoma
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study
to assess the efficacy and safety of lifileucel in combination with pembrolizumab
compared with pembrolizumab alone in participants with untreated, unresectable or
metastatic melanoma. Participants randomized to... expand
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period. Type: Interventional Start Date: Mar 2023 |
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants...
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension
MSA - Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and
durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks
of treatment. This study includes 4 periods: Screening, open label, randomized
withdrawal, and long-term treatment extension... expand
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE). Type: Interventional Start Date: Jun 2023 |
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
The purpose of this study is to evaluate the safety, and tolerability and efficacy of
VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic
fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR
modulator therapy. expand
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy. Type: Interventional Start Date: Feb 2023 |
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral...
SWOG Cancer Research Network
Malignant Solid Neoplasm
This phase III trial compares the effect of 3 study approaches in preventing
chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous
compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel
or docetaxel, can cause a nerve disorder called peripheral... expand
This phase III trial compares the effect of 3 study approaches in preventing chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel or docetaxel, can cause a nerve disorder called peripheral neuropathy, which can cause numbness, tingling, or pain in the arms and legs. The 3 study approaches will use a device, called the Paxman Limb Cryocompression System, made of wraps that cool and/or compress the arms and legs. This study may help researchers determine if any of the study approaches are able to prevent taxane chemotherapy from causing peripheral neuropathy. Type: Interventional Start Date: Jun 2023 |
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive...
Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Follicular Lymphoma
Richter Transformation Lymphoma
The purpose of this study is to assess the safety and tolerability of zilovertamab
vedotin as monotherapy and in combination in participants with select B-cell lymphomas
including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular
lymphoma (FL), and chronic lymphocytic... expand
The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. - Cohort A: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 2 prior systemic therapies including a Bruton's tyrosine kinase inhibition/inhibitor (BTKi), and post therapy chimeric antigen receptor T (CAR-T) cell therapy or ineligible for CAR-T cell therapy - Cohort B: Participants with relapsed or refractory RT disease after at least 1 prior systemic therapy - Cohort C: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 1 prior systemic therapy and no prior exposure to a non-covalent BTKi - Cohort D: Participants with relapsed or refractory FL and CLL relapsed or refractory disease after at least 2 prior systemic therapies and have no other available therapy - Cohort E: Participants with relapsed or refractory FL after at least 2 prior systemic therapies and have no other available therapy - Cohort F: Participants with relapsed or refractory CLL after at least 2 prior systemic therapies and have no other available therapy The primary study hypothesis is that zilovertamab vedotin monotherapy has an increased Objective Response Rate (ORR) per Lugano Response Criteria as assessed by blinded independent central review (BICR). Type: Interventional Start Date: Jul 2022 |
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD)...
Janssen Research & Development, LLC
Depressive Disorder, Major
Anhedonia
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo
as adjunctive therapy to an antidepressant in improving depressive symptoms in adult
participants with major depressive disorder (MDD) with moderate-to-severe anhedonia
(ANH+) who have had an inadequate response... expand
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI). Type: Interventional Start Date: Jun 2022 |
A Study of ASP3082 in Adults With Previously Treated Solid Tumors
Astellas Pharma Inc
Solid Tumor
Genes contain genetic code which tell the body which proteins to make. Many types of
cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are
looking for ways to stop the actions of abnormal proteins made from the mutated KRAS
gene. The so-called G12D mutation in the KRAS... expand
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. The so-called G12D mutation in the KRAS gene is common in people with some solid tumors. ASP3082 is a potential new treatment for solid tumors in people who have the G12D mutation in their KRAS gene. Before ASP3082 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. This information will help find a suitable dose and to check for potential medical problems from the treatment. People in this study will be adults with locally advanced, unresectable or metastatic solid tumors with the G12D mutation in their KRAS gene. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. They may have been previously treated with standard therapies. The main aims of the study are: to check the safety of ASP3082 by itself and together with cetuximab or chemotherapy, and how well it is tolerated, and to find a suitable dose of ASP3082 by itself and together with cetuximab or chemotherapy. This is an open-label study. This means that people in this study and clinic staff will know that they will receive ASP3082. This study will be in 2 parts. In Part 1, different small groups of people will receive lower to higher doses of ASP3082, by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP3082. The panel will do this for each group until all groups have received ASP3082 (by itself or together with cetuximab) or until suitable doses have been selected for Part 2. In Part 2, other different small groups of people will receive ASP3082 by itself or together with cetuximab or chemotherapy, with the most suitable doses worked out from Part 1. This will help find a more accurate dose of ASP3082 to use in future studies. ASP3082 (cetuximab or chemotherapy if used), will be given through a vein. This is called an infusion. Each treatment cycle is 21 or 28 days long. People will continue treatment until: they have medical problems from the treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop treatment. At some visits, other checks will include a medical examination, echocardiogram (ECHO) or multigated acquisition (MUGA) scan, blood and urine tests and vital signs. Vital signs include temperature, pulse, breathing rate, and blood pressure. (Blood oxygen levels will also be checked for people treated with ASP3082 together with cetuximab or chemotherapy.) Tumor samples will be taken during certain visits during treatment and when treatment has finished. People will visit the clinic on certain days during their treatment, with extra visits during the first 2 cycles of treatment. The study doctors will check for any medical problems from ASP3082 by itself or together with cetuximab or chemotherapy. At some visits, other checks will include a medical examination, echocardiogram (ECHO) or multigated acquisition (MUGA) scan, blood and urine tests and vital signs. Vital signs include temperature, pulse, breathing rate, and blood pressure. (Blood oxygen levels will also be checked for people treated with ASP3082 together with cetuximab or chemotherapy.) Tumor samples will be taken during certain visits during treatment and when treatment has finished. People will visit the clinic within 7 days after stopping treatment. The study doctors will check for any medical problems from ASP3082 by itself or together with cetuximab or chemotherapy. Other checks will include a medical examination, echocardiogram (ECHO) or multigated acquisition (MUGA) scan, urine and blood tests and vital signs. After this, people will continue to visit the clinic every 9 weeks to check the condition of their cancer. They will do this until 45 weeks after treatment stopped, or if their cancer is worse, they start other cancer treatment, or they ask to stop treatment. Also, people may visit the clinic at 30 days and 90 days after stopping treatment. At the 30-day visit, the study doctors will check for any medical problems from ASP3082 by itself or together with cetuximab or chemotherapy. People will have their vital signs checked and have some blood tests. At the 90-day visit, the study doctors will check for any medical problems from ASP3082 by itself or together with cetuximab or chemotherapy and people will have their vital signs checked. Type: Interventional Start Date: Jun 2022 |
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy...
Janssen Research & Development, LLC
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab
compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating
polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A. expand
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A. Type: Interventional Start Date: Sep 2022 |
Defining Endpoints in Becker Muscular Dystrophy
Virginia Commonwealth University
Becker Muscular Dystrophy
Muscular Dystrophies
Muscular Dystrophy in Children
Muscular Dystrophy, Becker
This is a 24-month, observational study of 50 participants with Becker muscular dystrophy
(BMD) expand
This is a 24-month, observational study of 50 participants with Becker muscular dystrophy (BMD) Type: Observational Start Date: Apr 2022 |
Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
Genentech, Inc.
Spinal Muscular Atrophy
A multi-center, longitudinal, prospective, non-comparative study to investigate the
long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment
as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with
spinal muscular atrophy (SMA). In this... expand
A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments. Type: Interventional Start Date: Jun 2022 |
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal...
Cogent Biosciences, Inc.
Advanced Gastrointestinal Stromal Tumors
Metastatic Cancer
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination
with sunitinib. This is a multi-part study that will enroll approximately 426 patients.
Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of
CGT9486 to be used in subsequent... expand
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner. Type: Interventional Start Date: Apr 2022 |
CureDuchenne Link®: A Resource for Research
CureDuchenne
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and
self- and/or caregiver-reported information from participants. Anyone over 4 weeks old
who has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join.
Parents or legal guardians can sign up... expand
CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and self- and/or caregiver-reported information from participants. Anyone over 4 weeks old who has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join. Parents or legal guardians can sign up their child(ren). Type: Observational [Patient Registry] Start Date: Jul 2021 |
- Previous
- Next